Protagonist Therapeutics (PTGX) Cash & Equivalents (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Cash & Equivalents data on file, last reported at $193.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 38.71% year-over-year to $193.7 million; the trailing twelve-month figure through Mar 2026 stood at $193.7 million (up 38.71% YoY), and the FY2025 full-year result was $128.4 million, up 32.02% from the prior year.
• Cash & Equivalents rose to $193.7 million in Q1 2026, from $128.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $355.6 million in Q2 2024 to a low of $97.2 million in Q4 2024.
• A 5-year average of $163.4 million and a median of $139.7 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 95.77% in 2023 and tumbled 52.61% in 2025, its largest moves.
• Tracing PTGX's Cash & Equivalents over 5 years: stood at $125.7 million in 2022, then surged by 48.5% to $186.7 million in 2023, then tumbled by 47.92% to $97.2 million in 2024, then jumped by 32.02% to $128.4 million in 2025, then surged by 50.88% to $193.7 million in 2026.
• Business Quant data shows PTGX's Cash & Equivalents at $193.7 million in Q1 2026, $128.4 million in Q4 2025, and $113.7 million in Q3 2025.